News
-
-
-
-
PRESS RELEASE
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
Bausch Health to acquire DURECT, advancing innovative treatment for alcoholic hepatitis patients with larsucosterol, an epigenetic modulator. Transaction focuses on improving liver disease outcomes globally -
-
-
-
PRESS RELEASE
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
Bausch Health appoints Michael Goettler and Sandra Leung to its Board of Directors, expanding the Board to twelve members. The new appointments bring extensive pharmaceutical industry expertise and leadership experience -
-
PRESS RELEASE
CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs
Bausch Health, Canada introduces CABTREO gel for acne treatment to public drug plans in Ontario, Nova Scotia, and federal programs, expanding access for Canadians
